| Literature DB >> 35880505 |
Ga Won Jeon1, Jang Hoon Lee2, Minkyung Oh3, Yun Sil Chang4.
Abstract
BACKGROUND: We aimed to determine the current survival rate and short-term outcomes of very-low-birth-weight infants (VLBWIs) in Korea, as well as whether the survival rate and short-term outcomes have improved over time since 2013, which was when the Korean Neonatal Network (KNN) was launched.Entities:
Keywords: Bronchopulmonary Dysplasia; Cerebral Intraventricular Hemorrhage; Infant Mortality; Infant, Premature; Infant, Very Low Birth Weight; Leukomalacia, Periventricular
Mesh:
Year: 2022 PMID: 35880505 PMCID: PMC9313972 DOI: 10.3346/jkms.2022.37.e229
Source DB: PubMed Journal: J Korean Med Sci ISSN: 1011-8934 Impact factor: 5.354
Maternal and neonatal characteristics
| Characteristics | Total | 2013–14 | 2015–16 | 2017–18 | 2019–20 | |||
|---|---|---|---|---|---|---|---|---|
| Maternal characteristics | ||||||||
| No. of births | ||||||||
| Singleton | 10,341 (63.1) | 65 (63–66) | 64 (62–65) | 64 (63–66) | 65 (63–66) | 0.032 | ||
| Twin | 5,347 (32.6) | 32 (31–34) | 32 (30–33) | 31 (30–33) | 32 (31–34) | 0.046 | ||
| ≥ Triplet | 702 (4.3) | 3 (2–4) | 5 (4–5) | 4 (4–5) | 3 (2–4) | < 0.001 | ||
| Method of pregnancy | ||||||||
| Natural | 12,169 (74.2) | 79 (77–80) | 76 (75–77) | 75 (74–76) | 79 (77–80) | < 0.001 | ||
| Assisted reproductive technology | 4,221 (25.8) | 21 (20–23) | 24 (23–25) | 25 (24–26) | 21 (20–23) | < 0.001 | ||
| Cesarean section | 13,010 (79.4) | 74 (73–76) | 79 (78–80) | 81 (80–82) | 82 (81–84) | 0.004 | ||
| Maternal diabetes during pregnancy | 1,665 (10.2) | 8 (7–9) | 9 (8–10) | 11 (10–12) | 13 (12–14) | < 0.001 | ||
| Maternal hypertension during pregnancy | 3,604 (22.0) | 20 (19–21) | 21 (20–22) | 23 (22–24) | 24 (23–26) | < 0.001 | ||
| Histologic chorioamnionitis | 4,722 (28.8) | 28 (26–29) | 29 (28–31) | 30 (29–31) | 28 (27–29) | 0.911 | ||
| Premature rupture of membrane | 5,703 (34.8) | 36 (34–37) | 35 (34–36) | 33 (32–35) | 35 (34–37) | 0.507 | ||
| Antenatal steroid therapy | 13,271 (81.0) | 74 (72–75) | 78 (77–80) | 84 (83–85) | 87 (86–88) | < 0.001 | ||
| Neonatal characteristics | ||||||||
| Initial resuscitation | 14,607 (89.7) | 89 (88–90) | 89 (88–90) | 91 (90–92) | 90 (89–91) | 0.545 | ||
| Intubation | 9,742 (66.7) | 75 (74–77) | 70 (69–72) | 62 (61–64) | 59 (58–61) | < 0.001 | ||
| Cardiac compression | 729 (5.0) | 5 (5–6) | 6 (5–6) | 5 (4–6) | 4 (3–4) | 0.005 | ||
| Respiratory distress syndrome | 12,620 (77.0) | 79 (77–80) | 78 (77–79) | 77 (76–78) | 74 (73–76) | 0.116 | ||
| Air leak | 876 (5.3) | 6 (5–7) | 5 (5–6) | 6 (5–6) | 4 (4–5) | 0.003 | ||
| Pulmonary hemorrhage | 979 (6.0) | 7 (6–8) | 6 (5–7) | 6 (5–6) | 5 (4–6) | < 0.001 | ||
| Postnatal steroid therapy | 3,791 (23.1) | 24 (22–25) | 21 (20–23) | 24 (23–25) | 24 (22–25) | 0.302 | ||
Values are expressed as number (%) or percentage (range of probability; 95% confidence interval).
Short-term outcomes according to gestational age
| Short-term outcomes | Total (N = 16,351) | Gestational age, wk | |||||
|---|---|---|---|---|---|---|---|
| 22–23 (n = 758) | 24–25 (n = 2,234) | 26–27 (n = 3,204) | 28–29 (n = 4,339) | 30–31 (n = 3,196) | ≥ 32 (n = 2,620) | ||
| Survival rate | 87 (86–87) | 33 (30–36) | 64 (62–66) | 85 (84–86) | 94 (94–95) | 97 (96–97) | 98 (97–98) |
| Apgar score at 1 min | 4.8 ± 1.8 | 2.5 ± 1.5 | 3.3 ± 1.7 | 3.7 ± 1.7 | 4.8 ± 1.9 | 5.5 ± 1.8 | 6.2 ± 1.8 |
| Apgar score at 5 min | 6.9 ± 1.6 | 4.7 ± 2.1 | 5.6 ± 1.9 | 6.0 ± 1.7 | 7.0 ± 1.6 | 7.5 ± 1.4 | 8.1 ± 1.3 |
| BT, °C | 36.1 ± 0.6 | 35.5 ± 1.0 | 36.0 ± 0.7 | 36.1 ± 0.6 | 36.3 ± 0.6 | 36.3 ± 0.5 | 36.2 ± 0.5 |
| RDS | 77 (76–78) | 98 (97–99) | 98 (98–99) | 96 (95–97) | 89 (88–90) | 63 (62–65) | 26 (24–27) |
| BPD | 32 (31–32) | 87 (83–91) | 72 (69–74) | 50 (48–52) | 28 (27–29) | 17 (16–19) | 7 (6–8) |
| PDA (requiring surgery) | 32 (31–34) | 44 (39–50) | 46 (43–49) | 38 (35–40) | 23 (21–25) | 18 (15–21) | 20 (15–25) |
| NEC (stage ≥ 2) | 7 (6–7) | 16 (13–18) | 15 (14–17) | 9 (8–10) | 5 (4–5) | 3 (2–3) | 1 (1–2) |
| ROP (requiring therapy) | 27 (26–28) | 61 (55–67) | 43 (40–46) | 25 (23–27) | 13 (11–15) | 5 (3–8) | 3 (0–6) |
| IVH (grade ≥ 3) | 9 (9–10) | 42 (38–46) | 26 (24–28) | 11 (10–12) | 5 (4–6) | 2 (2–3) | 1 (0–1) |
| PVL | 8 (7–8) | 15 (12–18) | 13 (12–15) | 10 (9–11) | 8 (7–9) | 5 (5–6) | 2 (2–3) |
| Sepsis | 20 (19–20) | 38 (35–42) | 38 (36–40) | 29 (28–31) | 17 (16–18) | 10 (9–11) | 6 (5–7) |
| Hospital stay, days | 58.1 ± 38.6 | 51.0 ± 68.9 | 87.6 ± 61.5 | 90.4 ± 42.1 | 67.1 ± 27.7 | 52.4 ± 23.6 | 39.3 ± 23.9 |
Values are expressed as mean ± pooled standard deviation or percentage (range of probability; 95% confidence interval).
BT = body temperature at admission, RDS = respiratory distress syndrome, BPD = bronchopulmonary dysplasia, PDA = patent ductus arteriosus, NEC = necrotizing enterocolitis, ROP = retinopathy of prematurity, IVH = intraventricular hemorrhage, PVL = periventricular leukomalacia.
Short-term outcomes according to era
| Short-term outcomes | 2013–14 (n = 3,519) | 2015–16 (n = 4,748) | 2017–18 (n = 4,260) | 2019–20 (n = 3,824) | |
|---|---|---|---|---|---|
| Survival rate | 87 (86–88) | 86 (85–87) | 86 (85–87) | 88 (87–89) | 0.771 |
| BPD | 31 (30–33) | 29 (27–30) | 33 (32–35) | 33 (32–35) | 0.019 |
| PDA (requiring surgery) | 35 (32–37) | 31 (28–33) | 33 (31–36) | 31 (29–34) | 0.364 |
| NEC (stage ≥ 2) | 7 (6–8) | 7 (6–7) | 7 (6–8) | 6 (5–7) | 0.481 |
| ROP (requiring therapy) | 28 (26–31) | 27 (25–29) | 27 (24–29) | 27 (24–29) | 0.471 |
| IVH (grade ≥ 3) | 11 (9–12) | 9 (8–10) | 9 (8–10) | 8 (7–9) | 0.003 |
| PVL | 9 (8–10) | 7 (6–8) | 8 (7–9) | 7 (6–8) | 0.042 |
| Sepsis | 21 (20–23) | 21 (20–22) | 20 (19–21) | 17 (15–18) | < 0.001 |
Values are expressed as percentage (range of probability; 95% confidence interval).
BPD = bronchopulmonary dysplasia, PDA = patent ductus arteriosus, NEC = necrotizing enterocolitis, ROP = retinopathy of prematurity, IVH = intraventricular hemorrhage, PVL = periventricular leukomalacia.
Trend analysis of survival rates according to gestational age from 2013 to 2020
| Gestational age, wk | 2013–14 (n = 3,519) | 2015–16 (n = 4,748) | 2017–18 (n = 4,260) | 2019–20 (n = 3,824) | |
|---|---|---|---|---|---|
| 22 | 17 (4–29) | 11 (3–20) | 17 (6–28) | 15 (2–29) | 0.883 |
| 23 | 42 (34–51) | 37 (29–44) | 35 (27–42) | 39 (31–47) | 0.559 |
| 24 | 62 (55–69) | 51 (46–57) | 56 (50–62) | 56 (50–62) | 0.477 |
| 25 | 77 (72–82) | 66 (61–71) | 64 (58–70) | 75 (70–80) | 0.583 |
| 26 | 79 (75–84) | 79 (75–82) | 82 (78–86) | 88 (85–92) | < 0.001 |
| 27 | 89 (86–93) | 87 (84–90) | 88 (85–91) | 87 (84–90) | 0.460 |
| 28 | 93 (91–96) | 93 (91–95) | 93 (91–95) | 95 (93–97) | 0.346 |
| 29 | 95 (93–97) | 95 (94–97) | 95 (93–97) | 96 (94–98) | 0.701 |
| 30 | 94 (92–96) | 98 (97–99) | 96 (94–98) | 97 (95–99) | 0.190 |
| 31 | 97 (95–99) | 97 (95–98) | 97 (95–99) | 98 (97–100) | 0.231 |
| ≥ 32 | 99 (97–100) | 98 (97–99) | 99 (99–100) | 98 (97–99) | 0.727 |
Values are expressed as percentage (range of probability; 95% confidence interval).
Trend analyses of major morbidities according to gestational age from 2013 to 2020
| Major morbidities | 2013–14 (n = 3,519) | 2015–16 (n = 4,748) | 2017–18 (n = 4,260) | 2019–20 (n = 3,824) | ||
|---|---|---|---|---|---|---|
| BPD | 31 (30–33) | 29 (27–30) | 33 (32–35) | 33 (32–35) | 0.019 | |
| 22–25 | 50 (45–54) | 51 (47–56) | 34 (29–38) | 40 (35–45) | 0.006 | |
| 26–27 | 62 (58–66) | 66 (63–69) | 58 (54–61) | 55 (51–59) | 0.078 | |
| 28–31 | 32 (29–34) | 35 (33–37) | 36 (34–38) | 35 (33–38) | 0.135 | |
| ≥ 32 | 8 (6–10) | 6 (4–8) | 7 (5–9) | 7 (5–9) | 0.757 | |
| PDA (requiring surgery) | 35 (32–37) | 31 (28–33) | 33 (31–36) | 31 (29–34) | 0.364 | |
| 22–25 | 48 (43–53) | 42 (37–47) | 48 (42–53) | 44 (39–50) | 0.770 | |
| 26–27 | 40 (35–45) | 37 (33–42) | 40 (35–45) | 34 (29–39) | 0.378 | |
| 28–31 | 22 (19–26) | 21 (17–24) | 21 (18–25) | 21 (17–24) | 0.675 | |
| ≥ 32 | 18 (10–27) | 17 (9–25) | 20 (10–30) | 27 (16–38) | 0.278 | |
| NEC (stage ≥ 2) | 7 (6–8) | 7 (6–7) | 7 (6–8) | 6 (5–7) | 0.481 | |
| 22–25 | 15 (13–18) | 15 (13–17) | 17 (14–19) | 14 (12–17) | 0.837 | |
| 26–27 | 9 (7–12) | 9 (7–11) | 11 (9–13) | 8 (6–9) | 0.504 | |
| 28–31 | 4 (3–4) | 4 (3–5) | 4 (3–5) | 4 (3–5) | 0.648 | |
| ≥ 32 | 2 (1–3) | 2 (1–3) | 1 (1–2) | 1 (0–2) | > 0.999 | |
| ROP (requiring therapy) | 28 (26–31) | 27 (25–29) | 27 (24–29) | 27 (24–29) | 0.471 | |
| 22–25 | 47 (42–53) | 47 (42–52) | 47 (42–52) | 42 (37–47) | 0.431 | |
| 26–27 | 22 (17–26) | 24 (20–28) | 26 (22–30) | 27 (23–31) | 0.174 | |
| 28–31 | 13 (9–17) | 10 (7–13) | 11 (8–14) | 11 (8–15) | 0.634 | |
| ≥ 32 | 14 (0–28) | 0 (0–0) | 3 (0–8) | 0 (0–0) | 0.033 | |
| IVH (grade ≥ 3) | 11 (9–12) | 9 (8–10) | 9 (8–10) | 8 (7–9) | 0.003 | |
| 22–25 | 32 (28–36) | 30 (27–33) | 29 (25–32) | 27 (23–30) | 0.114 | |
| 26–27 | 15 (12–17) | 10 (8–12) | 11 (9–13) | 10 (8–12) | 0.041 | |
| 28–31 | 4 (3–5) | 4 (3–5) | 4 (3–5) | 3 (2–4) | 0.518 | |
| ≥ 32 | 1 (0–1) | 1 (0–2) | 1 (0–2) | 0 (0–1) | 0.522 | |
| PVL | 9 (8–10) | 7 (6–8) | 8 (7–9) | 7 (6–8) | 0.042 | |
| 22–25 | 15 (12–18) | 11 (9–13) | 15 (12–18) | 14 (11–16) | 0.883 | |
| 26–27 | 14 (11–16) | 8 (7–10) | 10 (8–12) | 9 (7–11) | 0.026 | |
| 28–31 | 7 (6–9) | 7 (6–8) | 7 (6–8) | 6 (5–7) | 0.282 | |
| ≥ 32 | 3 (2–4) | 1 (1–2) | 2 (1–3) | 2 (1–3) | 0.451 | |
| Sepsis | 21 (20–23) | 21 (20–22) | 20 (19–21) | 17 (15–18) | < 0.001 | |
| 22–25 | 37 (33–41) | 44 (40–47) | 39 (35–42) | 32 (28–35) | 0.087 | |
| 26–27 | 32 (28–35) | 30 (27–33) | 29 (26–32) | 26 (23–29) | 0.058 | |
| 28–31 | 16 (14–17) | 15 (13–16) | 15 (13–16) | 11 (9–12) | < 0.001 | |
| ≥ 32 | 6 (4–8) | 6 (4–7) | 7 (5–8) | 5 (3–6) | 0.481 | |
Values are expressed as percentage (range of probability; 95% confidence interval).
BPD = bronchopulmonary dysplasia, PDA = patent ductus arteriosus, NEC = necrotizing enterocolitis, ROP = retinopathy of prematurity, IVH = intraventricular hemorrhage, PVL = periventricular leukomalacia.